Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Javier Garcia Perlaza, Rima Aziziyeh, Anna Zhou, Vitor De Sousa Barbosa, Jenny Amaya, Joaquin Caporale, Monica Elena Alva, Juan Forero, Straus Tanaka, Gaurav Suri & David Garcia. (2021) The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico. Journal of Medical Economics 24:1, pages 983-992.
Read now
Read now
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy & Wolfgang Willenbacher. (2019) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics 22:8, pages 766-776.
Read now
Read now
Athanasios Dellis & Athanasios Papatsoris. (2016) Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research 16:1, pages 5-10.
Read now
Read now
Maryam Iranikhah, Steve Stricker & Maisha Kelly Freeman. (2014) Future of bisphosphonates and denosumab for men with advanced prostate cancer. Cancer Management and Research 6, pages 217-224.
Read now
Read now
Articles from other publishers (11)
Aaron P. Mitchell, Akriti Mishra Meza, Katherine S. Panageas, Allison Lipitz-Snyderman, Azeez Farooki & Michael J. Morris. (2022) Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 26:1, pages 126-132.
Crossref
Crossref
Sherry S. Agabiti, Jin Li, Willie Dong, Michael M. Poe & Andrew J. Wiemer. (2019) Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition. Cell Death & Disease 10:10.
Crossref
Crossref
Jessica Y. Matuoka, James G. Kahn & Silvia R. Secoli. (2018) Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. The European Journal of Health Economics 20:4, pages 487-499.
Crossref
Crossref
Maria José Ribal, Juan Ignacio Martínez-Salamanca & Camilo García Freire. (2015) Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain. Prostate Cancer 2015, pages 1-6.
Crossref
Crossref
Axel S. Merseburger, Howard I. Scher, Joaquim Bellmunt, Kurt Miller, Peter F.A. Mulders, Arnulf Stenzl, Cora N. Sternberg, Karim Fizazi, Mohammad Hirmand, Billy Franks, Gabriel P. Haas, Johann de Bono & Ronald de Wit. (2015) Enzalutamide in European and North American men participating in the AFFIRM trial. BJU International 115:1, pages 41-49.
Crossref
Crossref
Cornelia Then, Emmo von Tresckow, Reiner Bartl & Fuat S. Oduncu. 2015. Medication-Related Osteonecrosis of the Jaws. Medication-Related Osteonecrosis of the Jaws
17
26
.
Alice Dragomir, Daniela Dinea, Marie Vanhuyse, Fabio L Cury & Armen G Aprikian. (2014) Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Services Research 14:1.
Crossref
Crossref
Vassilios Vassiliou, Panteleimon Kountourakis & Dimitrios Kardamakis. 2014. Bone Metastases. Bone Metastases
365
379
.
Thomas Roza, Lukman Hakim, Hendrik van Poppel & Steven Joniau. (2013) Bone-Targeted Therapies for Elderly Patients with Renal Cell Carcinoma: Current and Future Directions. Drugs & Aging 30:11, pages 877-886.
Crossref
Crossref
Kaitlin Koo, Kinsey Lam, Nicole Mittmann, Andre Konski, Kristopher Dennis, Liang Zeng, Henry Lam & Edward Chow. (2013) Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases. Supportive Care in Cancer 21:6, pages 1785-1791.
Crossref
Crossref
Vassilios Vassiliou. (2013) Management of Metastatic Bone Disease in the Elderly with Bisphosphonates and Receptor Activator of NF-kB Ligand Inhibitors: Effectiveness and Safety. Clinical Oncology 25:5, pages 290-297.
Crossref
Crossref